Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on July 10, 2020. The report addresses the status of the Company's listing on The Nasdaq Capital Market for its common stock (CTXR) and warrants (CTXRW).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary material event reported is the resolution of a delisting notice:
- Previous Status: On April 1, 2020, the Company received notice from Nasdaq that it failed to comply with Rule 5550(a)(2) because its closing bid price fell below $1.00 per share for 30 consecutive business days.
- Current Status: On July 10, 2020, the Company received notice that it regained compliance. The stock closed above $1.00 for 10 consecutive trading days between June 25 and July 9, 2020.
- Outcome: Nasdaq has officially closed the matter regarding the minimum bid price requirement.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of future risks beyond the immediate resolution of the listing compliance issue. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the current trading price of CTXR to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the Company's most recent 10-Q or 10-K filings for financial performance data, as this 8-K does not contain financial statements.
- Monitor future Nasdaq communications for any new compliance notices regarding market value or other listing standards.